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INTRODUCTION
Sub-acute sclerosing panencephalitis (SSPE) is a
progressive, grey matter neurodegenerative disorder
caused by a mutant measles virus.1 It is a potentially
preventable illness provided a proper measles immuni-
zation schedule is followed. The worldwide prevalence is
< 1 to 20/million population,2 however, figures are
substantially higher in the developing countries owing
predominantly to inadequate vaccination coverage.3,4
SSPE usually presents few years after the natural
measles infection with seizures and behavior changes
as the initial presentation of the disease. However, over
the years, measles virus has undergone modification
resulting in variable severity of presentation; vision loss
has been reported as the initial symptom in the patient
population by Dyken.5 SSPE causes a slow, progressive
decline in cognitive function but, fulminant course is not
uncommon.1,4,6,7 Treatment of SSPE is mainly supportive
and usually lifelong. Specific therapy with immune
modulators has been tried but is still controversial.
Atypical presentation may be seen and can be a
challenge to diagnosis. In a developing country like
Pakistan, it is important to understand and comprehend
the clinical presentation and course of the disease, so
that effective preventive strategies can be planned.
Hence, an observational analysis of SSPE cases was
carried out to get an insight at the disease in the
population so that relevant data could be collected and
utilized in formulating national guidelines and/or
treatment plans to combat this lethal disease.
The objective of the study was to determine the clinical
and demographic characteristics of children diagnosed
with subacute sclerosing panencephalitis (SSPE).
METHODOLOGY
Children under 16 years of age discharged from
pediatric unit of AKUH with a diagnosis of SSPE from
January 2000 to June 2012 were included in the study.
Any patient who did not fulfill the diagnostic criteria of
SSPE was excluded from study.
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ABSTRACT
Objective: To determine the clinical and demographic characteristics of children diagnosed with Subacute sclerosing
panencephalitis (SSPE).
Study Design: Case series.
Place and Duration of Study: The Aga Khan University Hospital, Karachi, from January 2000 to June 2012.
Methodology: A retrospective analysis was done, regarding medical charts of 43 children under the age of 16 years with
a discharge diagnosis of SSPE. Demographic and clinical characteristics were recorded. Results were expressed as
percentages.
Results: Most of the 43 patients were male (72%). The average age at presentation was 8.7 years with average duration
of symptoms being 100.6 days. History of measles was present in 17 patients (39.5%). All children had seizures at
presentation and 65% had cognitive impairment. Most patients required poly therapy for control of seizures. Sodium
valproate was the most commonly used anti-epileptic agent; Isoprinosine was tried in 22 (51%) patients. CSF for anti-
measles antibodies was positive in approximately 86% of the 40 (93%) children. EEG showed burst suppression pattern
in 36 (83.7%) cases. Forty-two patients (97.6%) were discharged home in a vegetative state.
Conclusion: SSPE is progressive neurodegenerative disorder. It can be prevented by timely immunization against
measles. Measles antibody in the CSF is diagnostic for SSPE and is helpful in early diagnosis. Most patients experience
a gradual but progressive decline in motor and cognitive functions.
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The study was approved by the Ethical Review
Committee (ERC) of the Aga Khan University Hospital
(ERC Number 2038-Ped-ERC-11). This was a
retrospective chart review. Data on 43 children under 16
years of age diagnosed with SSPE admitted in the
Pediatric Neurology ward of Aga Khan University
Hospital (AKUH) was retrieved using ICD 10 discharge
codes. Medical charts of all children were reviewed for
demographics, related biochemistry and clinical
variables, therapeutic and diagnostic interventions, and
outcomes at discharge. SSPE case was defined as any
patient who had typical clinical, radiographic and
electroencephalographic (EEG) findings suggestive of
SSPE along with anti-measles antibodies and/or
oligoclonal bands in cerebrospinal fluid (CSF).8 Data
was analyzed using Statistical Package for Social
Sciences (SPSS) version 20 and results were expressed
as percentages.
RESULTS
A total of 52 charts were reviewed, but only 43 patients
fulfilled the inclusion criteria. There was a male
predominance (n=31) as compared to females (n=12).
Mean age at presentation was 8.7 years with a range of
1.8 - 14 years. Average duration of symptoms was 100.6
days. Minimum duration of symptoms was one week;
maximum duration being 2 years. Thirteen children
(30.2%) were vaccinated against measles and 19
(44.2%) were unimmunized.
Vaccination status for 11 (25.6%) children was not
known. Seventeen (39.5%) patients had a past history of
measles whereas there was no history of measles in 14
(32.6%) children. Past history of measles was not known
in 12 (27.9%) patients (Figure 1). Regarding clinical
presentation, seizures were present in all children
diagnosed with SSPE. Myoclonic seizures were the
most common seizures observed. They were seen in 32
(74.4%) patients. Nine (21%) children presented with
generalized tonic clonic and 2 (4.6%) with generalized
tonic seizures. Two (4.7%) patients presented with a
history of frequent falls. Behavior changes were reported
in 23 (53.5%) children at presentation. Twenty patients
(46.5%) exhibited extrapyramidal symptoms including
dystonia and choreoathetosis. As the disease progressed,
23 (53.5%) of these patients developed cognitive and
motor impairment as well.
All children underwent an eye examination. Only one
child had optic atrophy. Sodium valproate was the most
common anti-epileptic used. It was used in 37 (86%) of
these patients in combination with other antiepileptic
agents. Patients showed better response with poly-
therapy, a maximum of four agents was used at a time.
Isoprinosine, a specific immune modulator, was used in
22 (51.1%) patients; Isoprinosine with interferon beta
was tried in 2 (4.7%) patients. Nineteen (44.2%) patients
did not receive any specific medication for SSPE. Mean
hospital stay for our children was 7.25 days. A lumbar
puncture was done in 40 (93%) patients. CSF was
positive for anti-measles antibodies in 37 (86%) patients;
oligoclonal bands alone were positive in 3 (7%) patients;
oligoclonal bands and anti-measles antibodies were
positive in 9 (20.9%) patients. EEG was done in all
patients. It showed burst suppression characteristic of
SSPE in 36 (83.7%) cases. Four (9.3%) patients showed
multifocal spike and wave discharges whereas EEG in 3
(7%) children demonstrated diffuse encephalopathy.
Neuroimaging (MRI brain with contrast) was done in 23
(76.7%) patients. Five (21.7%) scans were suggestive of
frontal lobe changes; other MRI findings included
cerebral atrophy in 1 (4.3%) patient, white matter and
basal ganglia change in 2 (8.7%) patients.
MRI was normal in 15 (65.3) patients. Imaging was not
possible in the remaining 20 patients due to financial
constraints. All patients were discharged from the ward.
Forty two (97.7%) were in vegetative state and 1 (2.3%)
was in a state of deep coma.
DISCUSSION
This data revealed a male predilection which is in
accordance with the previous reports on SSPE.9,10
Mean age at presentation was 8.7 years. SSPE was
seen at a younger age in these children as compared to
what has been reported in the literature previously.11
Few studies have published an older age at presentation
of 9 - 11 years.12 Kondo et al. reported an elevated
occurrence of SSPE in Karachi children and attributed it
to measles infection in early age.3 Seven (41%) patients
had measles in early infancy affirming the same trend.
The duration of symptoms observed in this study
population was also variable; 7 days being the shortest
period of illness reported before diagnosis demons-
trating the fulminant course of the disease. However,
majority of these patients had an average course of
illness of 100.6 days. Bojinova et al. have observed
similar variation regarding duration of symptoms.11
Vaccine is the most important tool in the prevention of
this disorder. The trends in SSPE incidence correlate
with the improved immunization coverage across the
Figure 1: Characteristics of patients diagnosed with SSPE at the Pediatric
Unit of the Aga Khan University Hospital between 2000-2012.
 
globe.13 The current higher trends observed locally
reflect the pitfalls in the measles immunization coverage
at the national level. Tariq et al. have discussed the
Pakistan perspective of sub acute sclerosing
panencephalitis and commented on the lack of
commitment to universal immunization observed
nationwide.14
It is usual but not mandatory to have a past measles
infection, as patients can have subclinical measles or
poor host response to measles infection resulting in
subtle manifestations. Literature review supports a past
history of measles in only 50% of cases diagnosed with
SSPE.15,16 There was no clear history of measles in 28%
children.
Regarding the clinical course, it is not uncommon to
have cognitive decline or behavior changes before the
onset of seizures. Interestingly, patients in this study had
overlapping symptoms; many had cognitive/behavioral
changes with seizures at presentation. Dyken has also
observed similar trends in his study group.5 Malik et al.
have reported cognitive and behavioral impairment in
children aged 2-16 years presenting with SSPE.23
Myoclonic seizures (74.4%) are the most common
seizures seen in SSPE, which were also the most
common seizure type seen in our patient group. Akram
et al. have also reported myoclonic seizures as the most
frequently observed seizures in children presenting with
SSPE, followed by generalized tonic clonic seizures
affecting 16% of children in their study group.17
Generalized tonic and generalized tonic clonic seizures
have also been observed and documented by Milewska
et al.18 The late onset symptoms like choreoathetosis;
hypertonia, were seen in these patients. These have
been supported by certain studies in literature.11 Eye
changes have been reported in literature. Only one child
in this study had optic atrophy.19
SSPE patients are resistant to anti-epileptic agents for
control of seizures, as are most patients with
neurodegenerative diseases. Generally symptomatic
control is achieved by poly-therapy. Among these
patients, a minimum of 1 and maximum of 4 agents were
used. Sodium valproate was the most commonly used
drug (86%). Leviteracetam was used in one case
(4.7%).
The role of sodium valproate for the control of myoclonic
seizures is well established.20 Although specific therapy
is not strongly recommended, some schools of thought
support the use of Isoprinosine early in the course of
illness.21 The combined use of Isoprinosine and
interferon has shown clinical improvement and
prolonged survival in some patients, though these
agents need to be continued even after apparent
remission.
Raised CSF measles antibody titers are considered
diagnostic for subacute sclerosing panencephalitis.22 In
this study, approximately 86% of the children tested
positive for anti-measles antibody in the CSF.
Approximately 84% children showed burst suppression
pattern of SSPE. Malik et al. have reported that 6.2%
Pakistani children presenting for a first EEG have a burst
suppression pattern suggestive of SSPE. Correlation of
clinical findings and a past history of measles infection
with the abnormal EEG warrants measles antibody
testing in such children in order to arrive at a definitive
diagnosis.23 Akram et al. described 50 patients with
SSPE who were diagnosed on the basis of EEG and
CSF findings.17
MRI brain with contrast is another imaging modality that
is being used towards diagnosing SSPE, though neuro-
imaging is not diagnostic. It was done in 23 of these
patients. Abnormal scans suggestive of SSPE were
reported in 8 patients. Remaining MRIs were normal.
MRI findings are slow to evolve and MRI brain can be
usually normal in SSPE if done early in the course of
disease.24 This is in accordance with the normal MRI
observed in majority of these patients. On the contrary,
Kumar and colleagues from India have reported cerebral
atrophy and white matter changes in most of the MRIs
done in children diagnosed with SSPE.25 This difference
could be in part due to the clinical stage of the SSPE
during which an MRI was done. MRI done during stages
3 and 4 are more likely to be abnormal as MRI changes
depend significantly on the duration of the disease.7
All 43 patients were discharged alive from the hospital.
Forty two (97.7%) children were in vegetative state
which is in accordance with the natural disease course
of SSPE that establishes SSPE as a disease of
morbidity and not immediate mortality.
CONCLUSION
In this study, patients with SSPE has measles with
presence of anti-measles anti-bodies in CSF is more
sensitive for diagnosing SSPE than typical EEG and
MRI findings. Multiple anti-epileptics were generally
required for control of symptoms in these patients,
however, seizures became refractory to anti-epileptic
treatment as the disease progresses. Most patients go
through a phase of progressive disability before
succumbing to this fatal neurodegenerative disorder.
Considering the rising number of SSPE patients, the
need for global immunization could not be stressed
more. Routine, timely and large scale measles
vaccination remains the key for eliminating this lethal
disease.
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